Cutaneous mucormycosis, life-threatening unsuspected Mycosis; case report and review.
DOI:
https://doi.org/10.29176/2590843X.1701Keywords:
Cutaneous mucormycosis, Invasive fungal disease, Mucormycosis, ZygomycosisAbstract
Mucormycoses are infections with an aggressive behavior and high mortality caused by aseptate filamentous fungi that mainly affect immunocompromised individuals. The entrance gate of the fungus into the body corresponds to the different forms of clinical presentation. Early diagnostic suspicion and prompt initiation of treatment are required to improve prognosis.
We report the case of a 59-year-old woman, with no associated diseases, who after a blunt trauma presented an extensive area of necrosis located in the frontal region, with subsequent dissemination due to ocular and systemic involvement that resulted in fatal outcome. The diagnosis was based on clinical findings, direct examination with KOH taken by aspiration of ocular tissue and skin biopsy, in which thick hyaline hyphae with extensive suppurative necrosis were recognized. Based on this case, the most important characteristics of this disease are discussed.
Author Biographies
Adriana Zamudio, Médica residente de tercer año de Dermatología, Universidad de Cartagena, Departamento Clínico, Cartagena, Colombia.
Médica residente de tercer año de Dermatología, Universidad de Cartagena, Departamento Clínico, Cartagena, Colombia.
María Camila Vargas, Médica internista, Universidad de Cartagena, Departamento Clínico, Cartagena, Colombia.
Médica internista, Universidad de Cartagena, Departamento Clínico, Cartagena, Colombia.
Francisco Camacho, Docente de Dermatología, Universidad de Cartagena, Departamento Clínico, Cartagena, Colombia.
Docente de Dermatología, Universidad de Cartagena, Departamento Clínico, Cartagena, Colombia.
References
Hassan MIA, Voigt K. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol. 1 de abril de 2019;57(Supplement_2):S245-56.
Mendoza L, Vilela R, Voelz K, Ibrahim AS, Voigt K, Lee SC. Human Fungal Pathogens of Mucorales and Entomophthorales. Cold Spring Harb Perspect Med. noviembre de 2014;5(4).
Ruiz Camps I, Salavert Lletí M. [The treatment of mucormycosis (zygomycosis) in the 21st century]. Rev Iberoam Micol. 2018;35(4):217-21.
Kerstin Voigt; Paul M Kirk. Fungi: Classification of Zygomycetes: Reappraisal as Coherent Class Based on a Comparison between Traditional versus Molecular Systematics. En: Encyclopedia of Food Microbiology. Boston: Elsevier; 2014.
Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009;15:2-9.
Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. marzo de 2016;30(1):143-63.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(SUPPL. 1):23-34.
Suzuki Y, Togano T, Ohto H, Kume H. Visceral Mycoses in Autopsied Cases in Japan from 1989 to 2013: Incidence of Cases with Mucormycetes is Increasing. 2018;59(4):10.
Jundt JS, Wong MEK, Tatara AM, Demian NM. Invasive Cutaneous Facial Mucormycosis in a Trauma Patient. J Oral Maxillofac Surg. 2018;76(9):1930.e1-1930.e5.
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53.
Kato H, Foster CM, Karri K. Incidence, predisposing conditions and outcomes of cutaneous mucormycosis: A national database study. Mycoses. 2021;64(5):569-72.
Skiada A, Rigopoulos D, Larios G, Petrikkos G, Katsambas A. Global epidemiology of cutaneous zygomycosis. Clin Dermatol. 2012;30(6):628-32.
Nucci M, Engelhardt M, Hamed K. Mucormycosis in South America: A review of 143 reported cases. Mycoses. 2019;62(9):730-8.
Patiño JF, Castro D, Valencia A, Morales P. Necrotizing soft tissue lesions after a volcanic cataclysm. World J Surg. 1991;15(2):240-7.
Alvarez-Moreno CA, Cortes JA, Denning DW. Burden of fungal infections in Colombia. J Fungi. 2018;4(2):1-13.
Morales-López S, Ceballos-Garzón A, ParraGiraldo CM. Zygomycete Fungi Infection in Colombia: Literature Review. Curr Fungal Infect Rep. 2018;12(4):149-54.
Mrittika Sen SL, Lahane1 TP, Parekh1 R, Santosh G Honavar. Mucor in a Viral Land: A Tale of Two Pathogens. Indian J Ophthalmol. 2021;Volume 69(Issue 2).
Chambers CJ, Reyes Merin M, Fung MA, Huntley A, Sharon VR. Primary cutaneous mucormycosis at sites of insulin injection. Vol. 64, Journal of the American Academy of Dermatology. United States; 2011. p. e79-81.
Bouchara JP, Oumeziane NA, Lissitzky JC, Larcher G, Tronchin G, Chabasse D. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol. mayo de 1996;70(1):76-83.
Partida-Martinez LP, Hertweck C. Pathogenic fungus harbours endosymbiotic bacteria for toxin production. Nature. octubre de 2005;437(7060):884-8.
Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. Curr Opin Infect Dis. diciembre de 2013;26(6):508-15.
Howard DH. Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev. julio de 1999;12(3):394-404.
Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. diciembre de 1982;31(12):1109-14.
Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. marzo de 1994;45(3):667-71.
Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, et al. Mucormycosis during deferoxamine therapy is a siderophoremediated infection. In vitro and in vivo animal studies. J Clin Invest. mayo de 1993;91(5):1979-86.
Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. octubre de 2009;15 Suppl 5:41-5.
Spellberg B, Edwards JJ, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. julio de 2005;18(3):556-69.
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34.
Balasopoulou A, Κokkinos P, Pagoulatos D, Plotas P, Makri OE, Georgakopoulos CD, et al. Symposium Recent advances and challenges in the management of retinoblastoma Globe _ saving Treatments. BMC Ophthalmol. 2017;17(1):1.
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-21.
Shields BE, Rosenbach M, Brown-Joel Z, Berger AP, Ford BA, Wanat KA. Angioinvasive fungal infections impacting the skin: Background, epidemiology, and clinical presentation. J Am Acad Dermatol. 2019;80(4):869-880.e5.
Long B, Koyfman A. Mucormycosis: What emergency physicians need to know? Am J Emerg Med. 2015;33(12):1823-5.
Vulsteke JB, Deeren D. Cutaneous mucormycosis. Transpl Infect Dis. 2019;21(2):0-1.
Arnáiz-García ME, Alonso-Peña D, del Carmen González-Vela M, García-Palomo JD, Sanz-Giménez-Rico JR, Arnáiz-García AM. Cutaneous mucormycosis: report of five cases and review of the literature. J Plast Reconstr Aesthet Surg. 2009;62(11):434-41.
Tapia E O, Chahín A C, Concha F C. Mucormicosis cutánea primaria: a propósito de dos casos. Revisión de la literatura. Rev Chil Infectol. 2011;28(3):269-73.
Ruiz CE, Arango M, Correa AL, López LS, Restrepo A. Fascitis necrosante por Apophysomyces elegans, moho de la familia Mucoraceae, en paciente inmunocompetente. Biomédica. 2004;24(3):239.
Millon L, Scherer E, Rocchi S, Bellanger AP. Molecular strategies to diagnose mucormycosis. J Fungi. 2019;5(1):1-8.
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Chen SCA, et al. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. Int J Antimicrob Agents. 2019;53(5):589-97.
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828-37.
Van Burik JAH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Erratum: Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases (Clinical Infectious Diseases (April 1, 2006) 42 (e61-e65)). Clin Infect Dis. 2006;43(10):1376.
Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(March):S93-101.
Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): Emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004;17(6):517-25.
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
